Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2011

01.02.2011 | Bone and Soft Tissue Sarcomas

Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy

verfasst von: Ryan C. Fields, MD, Meera Hameed, MD, Li-Xuan Qin, PhD, Nicole Moraco, MA, Xiaoyu Jia, MS, Robert G. Maki, MD, PhD, Samuel Singer, MD, Murray F. Brennan, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue malignancy that typically presents with local invasion but rarely metastasizes. We examine clinicopathologic factors associated with disease-free survival (DFS) in patients with primary and recurrent DFSP and evaluate responses to multimodality therapy.

Materials and Methods

Patients treated for DFSP were identified in a prospectively maintained database. Clinicopathologic factors associated with DFS were analyzed using univariate and multivariate analysis.

Results

A total of 244 patients with DFSP were identified. Median follow-up was 50 months. A total of 14 patients had local recurrence (LR), and 2 patients had distant recurrence (DR), with a median time to recurrence of 35 months. At time of last follow-up, 70% and 47% of patients showed no evidence of disease (NED) in the primary (n = 197) and recurrent groups (n = 47), respectively. On univariate analysis, tumor location and depth were associated with DFS in the primary group, while margin status (R1 vs. R0) was associated with DFS in the LR group. On multivariate analysis, only depth (primary group) and margin status (LR group), remained significant. Also, 22 patients had therapy other than surgical resection: 14 radiotherapy, 4 tyrosine kinase inhibitor (TKI) only, 2 conventional chemotherapy only, and 2 chemotherapy plus TKI. Responses to other therapies were variable.

Conclusions

DFS after treatment for DFSP is strongly predicted by tumor depth in the primary setting and margin status in recurrent tumors. The treatment for DFSP in the primary or recurrent setting is excision with negative margins, resulting in low recurrence rates and infrequent metastatic spread. Multimodality treatment, especially TKI use, can be effective, but is not curative.
Literatur
1.
Zurück zum Zitat Lemm D, Mugge LO, Mentzel T, Hoffken K. Current treatment options in Dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135:653–65.PubMedCrossRef Lemm D, Mugge LO, Mentzel T, Hoffken K. Current treatment options in Dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009;135:653–65.PubMedCrossRef
2.
Zurück zum Zitat Sundram UN. Review: Dermatofibrosarcoma protuberans: histologic approach and updated treatment recommendations. Clin Adv Hematol Oncol. 2009;7:406–8.PubMed Sundram UN. Review: Dermatofibrosarcoma protuberans: histologic approach and updated treatment recommendations. Clin Adv Hematol Oncol. 2009;7:406–8.PubMed
3.
Zurück zum Zitat Gloster HM, Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355–74; quiz 375–6.PubMedCrossRef Gloster HM, Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355–74; quiz 375–6.PubMedCrossRef
4.
Zurück zum Zitat Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in Dermatofibrosarcoma protuberans. Am J Surg Pathol. 1988;12:287–93.PubMedCrossRef Wrotnowski U, Cooper PH, Shmookler BM. Fibrosarcomatous change in Dermatofibrosarcoma protuberans. Am J Surg Pathol. 1988;12:287–93.PubMedCrossRef
5.
Zurück zum Zitat Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high-grade”) Dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.PubMedCrossRef Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high-grade”) Dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.PubMedCrossRef
6.
Zurück zum Zitat Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA. Ring chromosomes in Dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol. 1995;147:1553–8.PubMed Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA. Ring chromosomes in Dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol. 1995;147:1553–8.PubMed
7.
Zurück zum Zitat Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in Dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95–8.PubMedCrossRef Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in Dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95–8.PubMedCrossRef
8.
Zurück zum Zitat Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from Dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623–6.PubMedCrossRef Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from Dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623–6.PubMedCrossRef
9.
Zurück zum Zitat McArthur G. Molecularly targeted treatment for Dermatofibrosarcoma protuberans. Semin Oncol. 2004;31:30–6.PubMedCrossRef McArthur G. Molecularly targeted treatment for Dermatofibrosarcoma protuberans. Semin Oncol. 2004;31:30–6.PubMedCrossRef
10.
Zurück zum Zitat McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol. 2006;18:341–6.PubMedCrossRef McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol. 2006;18:341–6.PubMedCrossRef
11.
Zurück zum Zitat McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases—five with metastasis. Ann Surg. 1967;166:803–16.PubMedCrossRef McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases—five with metastasis. Ann Surg. 1967;166:803–16.PubMedCrossRef
12.
Zurück zum Zitat Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711–20.PubMedCrossRef Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711–20.PubMedCrossRef
13.
Zurück zum Zitat Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669–75.PubMedCrossRef Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669–75.PubMedCrossRef
14.
Zurück zum Zitat Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM. Radiotherapy in the treatment of Dermatofibrosarcoma protuberans. Am J Clin Oncol. 2005;28:537–9.PubMedCrossRef Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM. Radiotherapy in the treatment of Dermatofibrosarcoma protuberans. Am J Clin Oncol. 2005;28:537–9.PubMedCrossRef
15.
Zurück zum Zitat Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol. 2000;57:175–81.PubMedCrossRef Sun LM, Wang CJ, Huang CC, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol. 2000;57:175–81.PubMedCrossRef
16.
Zurück zum Zitat DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for Dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008–16.PubMedCrossRef DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for Dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008–16.PubMedCrossRef
17.
Zurück zum Zitat Misset J, Kerob D, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: result of a multicentric phase II study on 25 patients. J Clin Oncol. 2007;25:10032. Misset J, Kerob D, Porcher R, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: result of a multicentric phase II study on 25 patients. J Clin Oncol. 2007;25:10032.
18.
Zurück zum Zitat McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced Dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–73.PubMedCrossRef McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced Dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–73.PubMedCrossRef
19.
Zurück zum Zitat Popov P, Bohling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for Dermatofibrosarcoma protuberans. Plast Reconstr Surg. 2007;119:1779–84.PubMedCrossRef Popov P, Bohling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for Dermatofibrosarcoma protuberans. Plast Reconstr Surg. 2007;119:1779–84.PubMedCrossRef
20.
Zurück zum Zitat Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for Dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341–5.PubMed Chang CK, Jacobs IA, Salti GI. Outcomes of surgery for Dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341–5.PubMed
21.
Zurück zum Zitat Khatri VP, Galante JM, Bold RJ, Schneider PD, Ramsamooj R, Goodnight JE, Jr. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 2003;10:1118–22.PubMedCrossRef Khatri VP, Galante JM, Bold RJ, Schneider PD, Ramsamooj R, Goodnight JE, Jr. Dermatofibrosarcoma protuberans: reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol. 2003;10:1118–22.PubMedCrossRef
22.
Zurück zum Zitat Koh CK, Ko CB, Bury HP, Wyatt EH. Dermatofibrosarcoma protuberans. Int J Dermatol. 1995;34:256–60.PubMedCrossRef Koh CK, Ko CB, Bury HP, Wyatt EH. Dermatofibrosarcoma protuberans. Int J Dermatol. 1995;34:256–60.PubMedCrossRef
23.
Zurück zum Zitat Garcia C, Viehman G, Hitchcock M, Clark RE. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability. Dermatol Surg. 1996;22:177–9.PubMedCrossRef Garcia C, Viehman G, Hitchcock M, Clark RE. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability. Dermatol Surg. 1996;22:177–9.PubMedCrossRef
24.
Zurück zum Zitat Massey RA, Tok J, Strippoli BA, Szabolcs MJ, Silvers DN, Eliezri YD. A comparison of frozen and paraffin sections in Dermatofibrosarcoma protuberans. Dermatol Surg. 1998;24:995–8.PubMedCrossRef Massey RA, Tok J, Strippoli BA, Szabolcs MJ, Silvers DN, Eliezri YD. A comparison of frozen and paraffin sections in Dermatofibrosarcoma protuberans. Dermatol Surg. 1998;24:995–8.PubMedCrossRef
25.
Zurück zum Zitat Gloster HM, Jr., Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:82–7.PubMedCrossRef Gloster HM, Jr., Harris KR, Roenigk RK. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:82–7.PubMedCrossRef
26.
Zurück zum Zitat Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of Dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.PubMedCrossRef Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of Dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997;37:600–13.PubMedCrossRef
27.
Zurück zum Zitat Mendoza CB Jr., Gerwig WH, Jr., Watne AL. Dermatofibrosarcoma protuberans with metastases treated with methotrexate. Am J Surg. 1970;120:119–21.PubMedCrossRef Mendoza CB Jr., Gerwig WH, Jr., Watne AL. Dermatofibrosarcoma protuberans with metastases treated with methotrexate. Am J Surg. 1970;120:119–21.PubMedCrossRef
28.
Zurück zum Zitat Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic Dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586–91.PubMedCrossRef Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic Dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586–91.PubMedCrossRef
29.
Zurück zum Zitat Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–25.PubMedCrossRef Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–25.PubMedCrossRef
30.
Zurück zum Zitat Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced Dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.PubMedCrossRef Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced Dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.PubMedCrossRef
31.
Zurück zum Zitat McArthur GA. Molecular targeting of Dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw. 2007;5:557–62.PubMed McArthur GA. Molecular targeting of Dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw. 2007;5:557–62.PubMed
Metadaten
Titel
Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy
verfasst von
Ryan C. Fields, MD
Meera Hameed, MD
Li-Xuan Qin, PhD
Nicole Moraco, MA
Xiaoyu Jia, MS
Robert G. Maki, MD, PhD
Samuel Singer, MD
Murray F. Brennan, MD
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1316-5

Weitere Artikel der Ausgabe 2/2011

Annals of Surgical Oncology 2/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.